Home/ Stocks/ LIXT

Lixte Biotechnology Holdings, Inc. Common Stock

LIXT XNAS

$5.16 +0.23 (+4.67%) ▲ 15-min delayed

Open

$4.94

High

$5.55

Low

$4.75

Volume

124.4K

Market Cap

$59.95M

About Lixte Biotechnology Holdings, Inc. Common Stock

Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 3 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-6,009,520	N/A
FY 2025	$0	$-6,009,520	N/A
Q3 2025	$0	$-1,980,398	$-0.33
Q2 2025	$0	$-775,673	$-0.29

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for LIXT yet. Check out our latest market news or earnings calendar.

Get LIXT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Lixte Biotechnology Holdings, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.